CA2960777A1 - Macrocyclic lrrk2 kinase inhibitors - Google Patents

Macrocyclic lrrk2 kinase inhibitors Download PDF

Info

Publication number
CA2960777A1
CA2960777A1 CA2960777A CA2960777A CA2960777A1 CA 2960777 A1 CA2960777 A1 CA 2960777A1 CA 2960777 A CA2960777 A CA 2960777A CA 2960777 A CA2960777 A CA 2960777A CA 2960777 A1 CA2960777 A1 CA 2960777A1
Authority
CA
Canada
Prior art keywords
6alkyl
halo
6a1ky1
optionally
independently substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2960777A
Other languages
English (en)
French (fr)
Inventor
Jan Hoflack
Petra Blom
Olivier Lavergne
Sylvie Gomez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ONCODESIGN SA
Original Assignee
ONCODESIGN SA
Ipsen Pharma SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ONCODESIGN SA, Ipsen Pharma SAS filed Critical ONCODESIGN SA
Publication of CA2960777A1 publication Critical patent/CA2960777A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA2960777A 2014-09-17 2015-09-17 Macrocyclic lrrk2 kinase inhibitors Abandoned CA2960777A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14290279 2014-09-17
EP14290279.0 2014-09-17
PCT/EP2015/071349 WO2016042089A1 (en) 2014-09-17 2015-09-17 Macrocyclic lrrk2 kinase inhibitors

Publications (1)

Publication Number Publication Date
CA2960777A1 true CA2960777A1 (en) 2016-03-24

Family

ID=51752058

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2960777A Abandoned CA2960777A1 (en) 2014-09-17 2015-09-17 Macrocyclic lrrk2 kinase inhibitors

Country Status (20)

Country Link
US (1) US10377772B2 (https=)
EP (1) EP3194405B1 (https=)
JP (1) JP2017529365A (https=)
KR (1) KR20170048599A (https=)
CN (1) CN107108641A (https=)
AU (1) AU2015316801B2 (https=)
BR (1) BR112017005299A2 (https=)
CA (1) CA2960777A1 (https=)
DK (1) DK3194405T3 (https=)
EA (1) EA032838B1 (https=)
ES (1) ES2717510T3 (https=)
HU (1) HUE043972T2 (https=)
IL (1) IL251054B (https=)
MX (1) MX2017003470A (https=)
PL (1) PL3194405T4 (https=)
SG (1) SG11201701936WA (https=)
TR (1) TR201904514T4 (https=)
TW (1) TW201625639A (https=)
WO (1) WO2016042089A1 (https=)
ZA (1) ZA201701841B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111221514B (zh) * 2020-01-13 2023-03-03 陕西心像信息科技有限公司 基于OsgEarth的三维可视化组件实现方法及系统
UA129879C2 (uk) * 2020-01-31 2025-08-27 Онкодизайн Пресіжн Медісін (Опм) Макроциклічні інгібітори rip2-кінази
CA3182162A1 (en) 2020-05-06 2021-11-11 Les Laboratoires Servier New macrocyclic lrrk2 kinase inhibitors
TW202304935A (zh) 2021-03-18 2023-02-01 法商施維雅藥廠 新穎的巨環lrrk2激酶抑制劑
EP4416133A1 (en) * 2021-10-11 2024-08-21 Baylor College of Medicine G-protein-coupled receptor regulators and methods of use thereof
JP2024541934A (ja) 2021-10-27 2024-11-13 ハー・ルンドベック・アクチエゼルスカベット Ｌｒｒｋ２阻害剤
CN117425660A (zh) * 2022-05-18 2024-01-19 上海翊石医药科技有限公司 一种芳杂环类化合物及其中间体、药物组合物和用途
AR130483A1 (es) 2022-09-15 2024-12-11 H Lundbeck As Inhibidores de la cinasa con repeticiones ricas en leucina 2 (lrrk2)
WO2024218296A1 (en) * 2023-04-20 2024-10-24 H. Lundbeck A/S Combination treatments comprising administration of leucine-rich repeat kinase 2 (lrrk2) inhibitors
TW202442652A (zh) * 2023-04-20 2024-11-01 丹麥商Ｈ 朗德貝克公司 富白胺酸重複激酶2（lrrk2）抑制劑
WO2024218288A1 (en) * 2023-04-20 2024-10-24 H. Lundbeck A/S Leucine-rich repeat kinase 2 (lrrk2) inhibitors
WO2024218285A1 (en) * 2023-04-20 2024-10-24 H. Lundbeck A/S Leucine-rich repeat kinase 2 (lrrk2) inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
SK283569B6 (sk) 1993-10-01 2003-09-11 Astra Aktiebolag Spôsob spracovania jemne deleného práškového liečiva, zariadenie na vykonávanie tohto spôsobu a aglomeráty vyrobené týmto spôsobom
EP0729758A3 (en) 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines for the treatment of neuronal and other diseases
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
HU228962B1 (en) 1996-07-24 2013-07-29 Bristol Myers Squibb Pharma Co Azolo triazines, pharmaceutical compositions containing them and use of the compounds
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
DE60130924T2 (de) 2000-12-28 2008-07-17 Ono Pharmaceutical Co. Ltd. Cyclopentaädüpyrazoloä1,5-aüpyrimidin-verbindung als crf-rezeptor antagonist
BR0210391A (pt) * 2001-06-12 2004-06-15 Elan Pharm Inc Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
WO2006045392A2 (en) 2004-10-21 2006-05-04 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Kaspp (lrrke) gene, its production and use for the detection and treatment of neurodegenerative disorders
NO323175B1 (no) 2004-12-23 2007-01-15 Jan O Aasly Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme
FI123725B (fi) 2005-08-01 2013-10-15 Reijo Viljanen Menetelmä sahalaitteen terän jännittämiseksi ja ohjaamiseksi sekä ohjaus- ja jännityslaitteet
NZ568325A (en) 2005-11-16 2011-05-27 S Bio Pte Ltd Macrocyclic oxygen linked pyrimidine derivatives
WO2009127642A2 (en) 2008-04-15 2009-10-22 Cellzome Limited Use of lrrk2 inhibitors for neurodegenerative diseases
MX2012003778A (es) 2009-09-29 2012-06-01 Glaxo Group Ltd Compuestos novedosos.
NZ604708A (en) * 2010-05-20 2015-05-29 Array Biopharma Inc Macrocyclic compounds as trk kinase inhibitors
WO2013001310A1 (en) * 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
BR112014007654A8 (pt) * 2011-09-30 2018-06-12 Ipsen Pharma Inibidores de lrrk2 quinase macrocíclicos.
CA2849999A1 (en) * 2011-09-30 2013-04-04 Oncodesign S.A. Macrocyclic flt3 kinase inhibitors

Also Published As

Publication number Publication date
EP3194405B1 (en) 2018-12-26
PL3194405T3 (pl) 2019-07-31
JP2017529365A (ja) 2017-10-05
ZA201701841B (en) 2019-08-28
BR112017005299A2 (pt) 2017-12-12
EP3194405A1 (en) 2017-07-26
MX2017003470A (es) 2017-08-07
US20170240565A1 (en) 2017-08-24
CN107108641A (zh) 2017-08-29
EA032838B1 (ru) 2019-07-31
AU2015316801A1 (en) 2017-04-27
SG11201701936WA (en) 2017-04-27
TW201625639A (zh) 2016-07-16
AU2015316801B2 (en) 2019-03-07
DK3194405T3 (en) 2019-04-15
KR20170048599A (ko) 2017-05-08
IL251054B (en) 2019-03-31
US10377772B2 (en) 2019-08-13
HUE043972T2 (hu) 2019-09-30
PL3194405T4 (pl) 2019-07-31
TR201904514T4 (tr) 2019-04-22
EA201790626A1 (ru) 2017-07-31
ES2717510T3 (es) 2019-06-21
IL251054A0 (en) 2017-04-30
WO2016042089A1 (en) 2016-03-24

Similar Documents

Publication Publication Date Title
CA2960777A1 (en) Macrocyclic lrrk2 kinase inhibitors
JP6082397B2 (ja) マクロ環状ｌｒｒｋ２キナーゼ阻害剤
CA3121408A1 (en) Heteroaromatic derivatives for use as regulator, preparation method therefor and use thereof
DK2970333T3 (en) MACROCYCLIC LRRK2 KINase INHIBITORS
CA2868156C (en) Substituted pyridopyrimidine compounds and their use as flt3 inhibitors
EP3638680B1 (en) Heteroaromatic compounds as vanin inhibitors
AU2016322813A1 (en) Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors
CA2906262A1 (en) Macrocyclic salt-inducible kinase inhibitors
KR102925665B1 (ko) 피롤로피리딘 유도체 및 단백질 키나아제 관련 질환의 예방 또는 치료에서의 사용을 위한 이의 용도
WO2014155300A2 (en) Substitued pyrimidine amine derivatives as tak-1 inhibitors
EP3481824B1 (en) 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ror1 activity
KR20200090636A (ko) 피롤로피리미딘 유도체 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
CA2958782C (en) Macrocyclic rip2 kinase inhibitors
IL297767A (en) Novel imidazolones as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
US11660303B2 (en) 2-phenylimidazo[4,5-b]pyridin-7-amine derivates useful as inhibitors of mammalian tyrosine kinase ROR1 activity
HK1240586A1 (zh) 大环lrrk2激酶抑制剂
EP2968326A1 (en) Macrocyclic salt-inducible kinase inhibitors
HK1219481B (en) Macrocyclic lrrk2 kinase inhibitors

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20200917